Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTK Cytokinetics	$34.31 +3.3%	$34.92	$29.31 ▼ $59.39	$4.11B	0.64	1.75 million shs	2.04 million shs
PCVX Vaxcyte	$30.00 +1.1%	$34.32	$27.66 ▼ $121.06	$3.89B	1.21	1.79 million shs	2.10 million shs
PRAX Praxis Precision Medicines	$48.46 +7.8%	$48.21	$26.70 ▼ $91.83	$1.02B	2.62	455,349 shs	488,018 shs
RNA Avidity Biosciences	$46.23 +1.0%	$33.50	$21.51 ▼ $56.00	$5.95B	0.95	1.81 million shs	2.59 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTK Cytokinetics	-2.58%	-9.16%	-10.21%	+8.56%	-40.44%
PCVX Vaxcyte	-0.77%	-12.01%	-17.42%	-1.26%	-61.91%
PRAX Praxis Precision Medicines	-2.15%	-12.02%	-11.06%	+20.44%	-11.52%
RNA Avidity Biosciences	-1.16%	+22.53%	+45.48%	+53.13%	-2.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership
CYTK Cytokinetics	4.145 of 5 stars	4.4	1.0	4.6	3.1	0.8
PCVX Vaxcyte	2.0268 of 5 stars	3.5	2.0	0.0	2.3	1.7
PRAX Praxis Precision Medicines	1.6333 of 5 stars	3.4	1.0	0.0	2.3	1.7
RNA Avidity Biosciences	2.6327 of 5 stars	4.5	1.0	0.0	3.1	0.8

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYTK Cytokinetics	2.88	Moderate Buy	$70.69	106.04% Upside
PCVX Vaxcyte	3.09	Buy	$136.50	355.00% Upside
PRAX Praxis Precision Medicines	2.78	Moderate Buy	$95.22	96.50% Upside
RNA Avidity Biosciences	3.06	Buy	$67.00	44.93% Upside

Current Analyst Ratings Breakdown

Latest PRAX, CYTK, RNA, and PCVX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	CYTK Cytokinetics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $77.00
8/8/2025	RNA Avidity Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$70.00 ➝ $75.00
8/8/2025	RNA Avidity Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$59.00 ➝ $62.00
8/8/2025	RNA Avidity Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00
8/7/2025	PCVX Vaxcyte	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/5/2025	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00 ➝ $115.00
7/30/2025	CYTK Cytokinetics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform
7/29/2025	PRAX Praxis Precision Medicines	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
7/18/2025	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00
7/11/2025	RNA Avidity Biosciences	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$70.00
7/10/2025	RNA Avidity Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$55.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYTK Cytokinetics	$18.47M	222.28	N/A	N/A	($1.15) per share	-29.83
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$26.52 per share	N/A
PRAX Praxis Precision Medicines	$8.55M	119.31	N/A	N/A	$23.90 per share	2.03
RNA Avidity Biosciences	$10.90M	545.64	N/A	N/A	$11.94 per share	3.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYTK Cytokinetics	-$589.53M	-$5.10	N/A	N/A	N/A	-707.17%	N/A	-45.52%	N/A
PCVX Vaxcyte	-$463.93M	-$4.11	N/A	N/A	N/A	N/A	-16.85%	-15.92%	N/A
PRAX Praxis Precision Medicines	-$182.82M	-$12.29	N/A	N/A	N/A	-2,137.48%	-60.07%	-54.84%	N/A
RNA Avidity Biosciences	-$322.30M	-$3.00	N/A	N/A	N/A	-4,136.00%	-26.96%	-24.57%	N/A

Latest PRAX, CYTK, RNA, and PCVX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025 & Study Result	PRAX Praxis Precision Medicines	-$3.40	N/A	N/A	N/A	$0.16 million	N/A
8/7/2025	Q2 2025	CYTK Cytokinetics	-$1.34	-$1.12	+$0.22	-$1.12	$1.95 million	$66.77 million
8/6/2025	Q2 2025	PCVX Vaxcyte	-$1.12	-$1.22	-$0.10	-$1.22	N/A	N/A
8/4/2025	Q2 2025 & Study Result	PRAX Praxis Precision Medicines	-$3.40	-$3.31	+$0.09	-$3.31	$0.15 million	N/A
5/14/2025	Q1 2025	PCVX Vaxcyte	-$1.02	-$1.04	-$0.02	-$1.04	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYTK Cytokinetics	N/A	6.76	6.76
PCVX Vaxcyte	N/A	11.11	11.11
PRAX Praxis Precision Medicines	N/A	6.31	6.31
RNA Avidity Biosciences	N/A	16.91	16.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYTK Cytokinetics	N/A
PCVX Vaxcyte	96.78%
PRAX Praxis Precision Medicines	67.84%
RNA Avidity Biosciences	N/A

Insider Ownership

Company	Insider Ownership
CYTK Cytokinetics	3.40%
PCVX Vaxcyte	3.10%
PRAX Praxis Precision Medicines	2.70%
RNA Avidity Biosciences	3.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYTK Cytokinetics	250	119.66 million	115.59 million	Optionable
PCVX Vaxcyte	160	129.82 million	125.80 million	Optionable
PRAX Praxis Precision Medicines	110	21.05 million	20.48 million	Optionable
RNA Avidity Biosciences	190	128.65 million	123.73 million	Optionable

PRAX, CYTK, RNA, and PCVX Headlines

Recent News About These Companies

Avidity Biosciences (NASDAQ:RNA) Shares Gap Down on Insider Selling

August 12 at 10:32 AM | marketbeat.com

What is Leerink Partnrs' Estimate for RNA FY2027 Earnings?

August 12 at 4:55 AM | marketbeat.com

Mackenzie Financial Corp Invests $213,000 in Avidity Biosciences, Inc. (NASDAQ:RNA)

August 11 at 4:35 AM | marketbeat.com

Wells Fargo & Company Forecasts Strong Price Appreciation for Avidity Biosciences (NASDAQ:RNA) Stock

August 11 at 2:51 AM | americanbankingnews.com

Troy Edward Wilson Sells 65,554 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) Stock

August 10 at 6:01 PM | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Steven George Hughes Sells 81,434 Shares

August 10 at 6:00 PM | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Director Sells $5,119,150.00 in Stock

August 10 at 5:58 PM | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Eric Mosbrooker Sells 130,807 Shares

August 10 at 5:58 PM | marketbeat.com

The Avidity Biosciences, Inc. (NASDAQ:RNA) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

August 10 at 2:15 PM | finance.yahoo.com

Avidity (RNA) Q2 Revenue Jumps 88%

August 9 at 11:13 PM | theglobeandmail.com

Wells Fargo & Company Issues Positive Forecast for Avidity Biosciences (NASDAQ:RNA) Stock Price

August 9 at 11:43 AM | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Price Target Raised to $62.00 at Barclays

August 9 at 9:53 AM | marketbeat.com

Avidity Biosciences' (RNA) "Buy" Rating Reaffirmed at Chardan Capital

August 9 at 9:10 AM | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells $3,480,489.16 in Stock

August 9 at 6:26 AM | insidertrades.com

Avidity Biosciences Signs Manufacturing Agreement with Lonza

August 8, 2025 | theglobeandmail.com

Avidity Biosciences price target raised to $75 from $70 at Wells Fargo

August 8, 2025 | msn.com

Novartis Continues Hunt for New Assets With Rumored Takeover of RNA Specialist Avidity

August 8, 2025 | biospace.comB

Avidity (RNA) Gets 26% Jump on Potential Takeover

August 8, 2025 | msn.com

Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights

August 7, 2025 | prnewswire.com

Avidity Biosciences (NASDAQ:RNA) Stock Price Up 18.4% - Time to Buy?

August 7, 2025 | marketbeat.com

Rumour mill says Novartis may want to buy Avidity

August 7, 2025 | pharmaphorum.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PRAX, CYTK, RNA, and PCVX Company Descriptions

Cytokinetics NASDAQ:CYTK

$34.31 +1.08 (+3.25%)

Closing price 04:00 PM Eastern

Extended Trading

$34.95 +0.64 (+1.88%)

As of 06:26 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Vaxcyte NASDAQ:PCVX

$30.00 +0.33 (+1.11%)

Closing price 04:00 PM Eastern

Extended Trading

$30.74 +0.74 (+2.47%)

As of 05:59 PM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Praxis Precision Medicines NASDAQ:PRAX

$48.46 +3.51 (+7.81%)

Closing price 04:00 PM Eastern

Extended Trading

$48.43 -0.03 (-0.06%)

As of 05:06 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Avidity Biosciences NASDAQ:RNA

$46.23 +0.45 (+0.98%)

Closing price 04:00 PM Eastern

Extended Trading

$46.18 -0.04 (-0.10%)

As of 06:25 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time